Evidence map›Paper›PMID 40866714›Full record

ArticleNature2025

Retraction Note: Crystal structures of agonist-bound human cannabinoid receptor CB

Tian Hua, Kiran Vemuri, Spyros P Nikas, Robert B Laprairie, Yiran Wu, Lu Qu, Mengchen Pu, Anisha Korde, Shan Jiang, Jo-Hao Ho and 10 more

Abstract readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Side-Chain Homologs of ΔMolecular neurobiology · 2026
    Article
  2. GαNature communications · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Tian HuaiHuman Institute, ShanghaiTech University, Shanghai, China.
Kiran Vemuri *Center for Drug Discovery, Department of Pharmaceutical Sciences; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.
Spyros P Nikas *Center for Drug Discovery, Department of Pharmaceutical Sciences; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.
Robert B LaprairieDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida, USA.
Yiran WuiHuman Institute, ShanghaiTech University, Shanghai, China.
Lu QuiHuman Institute, ShanghaiTech University, Shanghai, China.
Mengchen PuiHuman Institute, ShanghaiTech University, Shanghai, China.
Anisha KordeCenter for Drug Discovery, Department of Pharmaceutical Sciences; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.
Shan JiangCenter for Drug Discovery, Department of Pharmaceutical Sciences; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.
Jo-Hao HoDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida, USA.
Gye Won HanDepartments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, California, USA.
Kang DingiHuman Institute, ShanghaiTech University, Shanghai, China.
Xuanxuan LiComplex Systems Division, Beijing Computational Science Research Center, Beijing, China.
Haiguang LiuComplex Systems Division, Beijing Computational Science Research Center, Beijing, China.
Michael A HansonGPCR Consortium, San Marcos, California, USA.
Suwen ZhaoiHuman Institute, ShanghaiTech University, Shanghai, China. zhaosw@shanghaitech.edu.cn.
Laura M BohnDepartments of Molecular Medicine and Neuroscience, The Scripps Research Institute, Jupiter, Florida, USA. lbohn@scripps.edu.
Alexandros MakriyannisCenter for Drug Discovery, Department of Pharmaceutical Sciences; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA. a.makriyannis@northeastern.edu.
Raymond C StevensiHuman Institute, ShanghaiTech University, Shanghai, China.
Zhi-Jie LiuiHuman Institute, ShanghaiTech University, Shanghai, China. liuzhj@shanghaitech.edu.cn.

Funding

Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0M
Cannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1M
Structure Function of CB1 Cannabinoid ReceptorR01DA041435 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATRITCH, VSEVOLOD, MAKRIYANNIS, ALEXANDROS · 2016 to 2020
$3.6M
NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA041435NIDA NIH HHS R37 DA023142
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40866714
PMCPMC12947850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.